CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 38 enrolled
Drug / intervention
metoprolol succinate (Toprol XL) +1 moredrug
Likely dose
metoprolol succinate (Toprol XL) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01052428
NCT01052428Phase 3Completed

Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)

University of Alabama at Birmingham·interventional·Posted Jan 20, 2010·Updated Nov 22, 2012

In Brief

A Phase 3 clinical trial evaluating metoprolol succinate (Toprol XL) and Placebo for Mitral Regurgitation. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The investigators hypothesize that beta-1 receptor blockade (ß1-RB) attenuates extracellular matrix (ECM) degradation and progressive adverse Left Ventricular (LV) remodeling and failure in the volume overload of mitral regurgitation (MR). Patients without coronary artery disease and moderate MR, as assessed by color/flow Doppler echocardiography, will be randomized to ß1-RB vs. placebo to address the following aims: \*Aim 1: Establish whether ß1-RB attenuates adverse LV remodeling compared to placebo in patients with non-surgical, chronic MR. Using 3-dimensional magnetic resonance imaging (MRI) and tissue tagging, LV function and geometry will be assessed at baseline and every 6 months for up to 2 years. Aim 2: Determine whether indices of inflammation correlate with degree of LV remodeling and whether ß1-RB decrease indices of inflammation and collagen turnover. At the time of MRI, blood samples for collagen breakdown products, matrix metalloproteinase (MMP) activity, and markers of excess production of reactive inflammatory species (RIS) will be obtained and related to changes in LV remodeling defined by serial 3-dimensional MRI and tissue tagging.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 20, 2010
Enrollment StartAug 1, 2004
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 16.4 years ago

Interventions

metoprolol succinate (Toprol XL)drug

Toprol XL 100 mg once a day for 2 years

Placebodrug

Placebo 100 mg once a day for 2 years